title: Re: Boyer et al.: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema (Ophthalmology 2014;121:1904-14).
authors.affiliation: Center for Ophthalmology, Eberhard-Karl University Tuebingen, Eye Center, Albert-Ludwigs-University Freiburg, Tuebingen and Freiburg, Germany. Electronic address: focke.ziemssen@med.uni-tuebingen.de.
authors.forename: Focke
authors.initials: F
authors.lastname: Ziemssen
authors.affiliation: Center for Ophthalmology, Eberhard-Karl University Tuebingen, Eye Center, Albert-Ludwigs-University Freiburg, Tuebingen and Freiburg, Germany.
authors.forename: Hansjürgen
authors.initials: H
authors.lastname: Agostini
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male
chemical_list: D000893:Anti-Inflammatory Agents; D003907:Dexamethasone